Impact of Dexamethasone Responsiveness on Long Term Outcome in Patients with Newly Diagnosed Multiple Myeloma

Dexamethasone (Dex), alone or in combination, is commonly used for treating multiple myeloma. Dex as single agent for initial therapy of myeloma results in overall response rates of 50-60%. It is unclear whether steroid responsiveness reflects any biological characteristic that impacts long-term out...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Sinha, Shirshendu, Rajkumar, S. Vincent, Lacy, Martha Q., Hayman, Suzanne R., Buadi, Francis K., Dispenzieri, Angela, Dingli, David, Kyle, Robert A., Gertz, Morie A., Kumar, Shaji
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2009
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2864312/
https://ncbi.nlm.nih.gov/pubmed/19958361
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2009.08023.x
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller